Erratum: Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Identifying the differentially expressed microRNAs in esophagus squamous cell carcinoma of Kazakh patients in Xinjiang.Oncology letters · 2019
   Article
2. MicroRNA-153 suppresses human laryngeal squamous cell carcinoma migration and invasion by targeting the SNAI1 gene.Oncology letters · 2018
   Article
3. Research progress on the relationship between zinc deficiency, related microRNAs, and esophageal carcinoma.Thoracic cancer · 2017
   Review

Corrections and comments

• Erratum for
  Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract